Literature DB >> 6922723

Purification and properties of human low molecular weight kininogen.

W Müller-Esterl, M Vohle-Timmermann, B Boos, B Dittman.   

Abstract

A three-step isolation procedure has been developed for human low molecular weight kininogen resulting in a 385-fold purification of the protein from plasma with an accumulative yield of 8.4%. Human low molecular weight kininogen is a single-chain glycoprotein of apparent molecular weight of 68,000 with a blocked amino-terminus. In the absence of dissociating agents, low molecular weight kininogen reversibly forms homo-oligomers with apparent Mr 185,000 (dimer) to 780,000 (decamer). Limited proteolysis of low molecular weight kininogen by tissue kallikrein liberates kinin and results in the formation of a two-chain molecular with an Mr 62,000 heavy chain of apparent Mr 4000.

Entities:  

Mesh:

Substances:

Year:  1982        PMID: 6922723     DOI: 10.1016/0167-4838(82)90480-0

Source DB:  PubMed          Journal:  Biochim Biophys Acta        ISSN: 0006-3002


  5 in total

Review 1.  FXII.

Authors:  G Fuhrer; M J Gallimore; W Heller; H E Hoffmeister
Journal:  Blut       Date:  1990-11

2.  High molecular weight kininogen is an inhibitor of platelet calpain.

Authors:  A H Schmaier; H Bradford; L D Silver; A Farber; C F Scott; D Schutsky; R W Colman
Journal:  J Clin Invest       Date:  1986-05       Impact factor: 14.808

3.  Arrangement of the disulphide bridges in human low-Mr kininogen.

Authors:  J Kellermann; C Thelen; F Lottspeich; A Henschen; R Vogel; W Müller-Esterl
Journal:  Biochem J       Date:  1987-10-01       Impact factor: 3.857

4.  High-affinity binding of two molecules of cysteine proteinases to low-molecular-weight kininogen.

Authors:  B Turk; V Stoka; I Björk; C Boudier; G Johansson; I Dolenc; A Colic; J G Bieth; V Turk
Journal:  Protein Sci       Date:  1995-09       Impact factor: 6.725

Review 5.  Blood Clotting and the Pathogenesis of Types I and II Hereditary Angioedema.

Authors:  Steven de Maat; Kusumam Joseph; Coen Maas; Allen P Kaplan
Journal:  Clin Rev Allergy Immunol       Date:  2021-05-06       Impact factor: 8.667

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.